Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Kao

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Science Translational Medicine|September 17, 2025
PD-1-targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancerIrene Fusi, Clara Serger, Petra Herzig, et al.
Journal for Immunotherapy of Cancer|November 1, 2022
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumorsMarina Natoli, Klas Hatje, Pratiksha Gulati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the EsophagusLucjan Wyrwicz, Arunee Dechaphunkul, Jong-Seok Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.
Journal for Immunotherapy of Cancer|June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumorsKristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Science Translational Medicine|September 17, 2025
PD-1-targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancerIrene Fusi, Clara Serger, Petra Herzig, et al.
Journal for Immunotherapy of Cancer|November 1, 2022
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumorsMarina Natoli, Klas Hatje, Pratiksha Gulati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the EsophagusLucjan Wyrwicz, Arunee Dechaphunkul, Jong-Seok Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.
Journal for Immunotherapy of Cancer|June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumorsKristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
Pageof 2